Innocare 诺诚健华
19 significant filings since 29 May 2026: 15 on equity incentive, 2 on major holder selling and 1 on major contract or bid won, and 1 other kind. The latest, on 24 Sep 2026: 诺诚健华医药有限公司关于子公司与礼来公司签署研发合作及授权许可协议的公告.
自 29 May 2026 起有 19 份重大公告：equity incentive 15 份、major holder selling 2 份、major contract or bid won 1 份，另有 1 类。最新一份（24 Sep 2026）：诺诚健华医药有限公司关于子公司与礼来公司签署研发合作及授权许可协议的公告。
| FY2026 | FY2027 | |
|---|---|---|
| Now 当前 | 0.14 | 0.11 |
| 7 days ago | 0.15 | 0.11 |
| 30 days ago | 2 brokers | 2 brokers |
| 60 days ago | 1 broker | 1 broker |
| 90 days ago | 0.04 | 0.07 |
Consensus is the median of each broker's latest forecast from the 120 days before each date. With fewer than 3 brokers, the broker count is shown. 一致预期为各券商在该日期前 120 天内最新预测的中位数；不足 3 家时显示券商数。
Consensus moved from -0.06 in Sep 2024 to 0.14 in Sep 2026 (+333.3%). 一致预期从 Sep 2024 的 -0.06 变为 Sep 2026 的 0.14 (+333.3%)。 The shaded band runs from the lowest to the highest broker forecast.
| FY2026 | FY2027 | |
|---|---|---|
| Last 30 days | ▲ 1 ▼ 0 = 0 | ▲ 1 ▼ 0 = 0 |
| Last 90 days | ▲ 3 ▼ 0 = 0 | ▲ 2 ▼ 1 = 0 |
Each broker's latest forecast is compared with its previous forecast for the same year. A move within 0.5% counts as unchanged. 每家券商的最新预测与其对同一年度的上一次预测比较，变动在 0.5% 以内视为不变。
A surprise needs at least 3 brokers forecasting in the 120 days before the filing. FY2025 had 0 and FY2024 had 0.